D
BioNTech SE BNTX
NASDAQ
Recommendation
Prev Close
Volume
--
Avg Vol (90D)
Market Cap
Dividend & Yield
--
52-Week Range
P/E (TTM)
EPS (TTM)
D
Sell 2/8/2024Downgrade
BioNTech SE (BNTX) was downgraded to D+ from C- on 2/8/2024 due to a decline in the volatility index, total return index and efficiency index.
C
Hold 1/16/2024Downgrade
BioNTech SE (BNTX) was downgraded to C- from C on 1/16/2024 due to a decline in the volatility index, total return index and valuation index.
C
Hold 11/7/2023Upgraded
BioNTech SE (BNTX) was upgraded to C from C- on 11/7/2023 due to a significant increase in the growth index and efficiency index. Total revenue increased 433.83% from $182.54M to $974.46M, earnings per share increased from -$0.8599 to $0.7292, and net income increased 184.34% from -$207.25M to $174.8M.
C
Hold 8/8/2023Downgrade
BioNTech SE (BNTX) was downgraded to C- from C on 8/8/2023 due to a significant decline in the growth index, total return index and valuation index. EBIT declined 164.79% from $826.72M to -$535.65M, earnings per share declined from $2.1984 to -$0.8599, and total revenue declined 86.67% from $1.37B to $182.54M.
C
Hold 4/28/2023Downgrade
BioNTech SE (BNTX) was downgraded to C from C+ on 4/28/2023 due to a large decline in the growth index and total return index. Operating cash flow declined 82.41% from $4.82B to $847.24M.
C
Hold 12/7/2022Upgraded
BioNTech SE (BNTX) was upgraded to C+ from C on 12/7/2022 due to a major increase in the growth index, efficiency index and solvency index. Operating cash flow increased 15.29% from $4.17B to $4.81B, EBIT increased 8.28% from $1.8B to $1.95B, and the quick ratio increased from 5.03 to 5.24.
C
Hold 9/23/2022Downgrade
BioNTech SE (BNTX) was downgraded to C from C+ on 9/23/2022 due to a noticeable decline in the growth index, total return index and solvency index. EBIT declined 65.26% from $5.19B to $1.8B, earnings per share declined from $15.9678 to $6.8705, and total revenue declined 52.37% from $7.15B to $3.4B.
C
Hold 6/30/2022Upgraded
BioNTech SE (BNTX) was upgraded to C+ from C on 6/30/2022 due to an increase in the total return index.
C
Hold 6/14/2022Downgrade
BioNTech SE (BNTX) was downgraded to C from C+ on 6/14/2022 due to a decline in the total return index, volatility index and solvency index.
C
Hold 4/18/2022Upgraded
BioNTech SE (BNTX) was upgraded to C+ from C on 4/18/2022 due to a noticeable increase in the efficiency index, valuation index and total return index. Total capital increased 32.99% from $10.43B to $13.87B.
C
Hold 3/7/2022Downgrade
BioNTech SE (BNTX) was downgraded to C from C+ on 3/7/2022 due to a decline in the volatility index and total return index.
C
Hold 11/26/2021Downgrade
BioNTech SE (BNTX) was downgraded to C+ from B- on 11/26/2021 due to a decline in the volatility index and valuation index.
B
Buy 11/11/2021Upgraded
BioNTech SE (BNTX) was upgraded to B- from C+ on 11/11/2021 due to a major increase in the valuation index, volatility index and growth index. Operating cash flow increased 1,563.14% from -$120.89M to $1.77B, total revenue increased 12.13% from $6.4B to $7.17B, and earnings per share increased from $12.981 to $14.5554.
C
Hold 10/7/2021Downgrade
BioNTech SE (BNTX) was downgraded to C+ from B- on 10/7/2021 due to a substantial decline in the total return index and volatility index.
B
Buy 10/1/2021Downgrade
BioNTech SE (BNTX) was downgraded to B- from B on 10/1/2021 due to a decline in the volatility index and total return index.
B
Buy 8/11/2021Upgraded
BioNTech SE (BNTX) was upgraded to B from C+ on 8/11/2021 due to a substantial increase in the valuation index, total return index and efficiency index. Net income increased 147.11% from $1.36B to $3.36B, and total capital increased 110.05% from $3.25B to $6.83B.
C
Hold 7/23/2021Downgrade
BioNTech SE (BNTX) was downgraded to C+ from B- on 7/23/2021 due to a decline in the valuation index.
B
Buy 7/8/2021Upgraded
BioNTech SE (BNTX) was upgraded to B- from C+ on 7/8/2021 due to an increase in the total return index and valuation index.
C
Hold 6/11/2021Downgrade
BioNTech SE (BNTX) was downgraded to C+ from B- on 6/11/2021 due to a decline in the valuation index.
B
Buy 5/18/2021Upgraded
BioNTech SE (BNTX) was upgraded to B- from C- on 5/18/2021 due to a significant increase in the growth index, valuation index and total return index. EBIT increased 18,204.19% from $10.23M to $1.87B, total revenue increased 499.64% from $411.77M to $2.47B, and earnings per share increased from $1.443 to $5.2917.
C
Hold 4/8/2021Upgraded
BioNTech SE (BNTX) was upgraded to C- from D+ on 4/8/2021 due to a substantial increase in the efficiency index, growth index and total return index. Total revenue increased 421.94% from $78.89M to $411.77M, net income increased 278.06% from -$245.63M to $437.36M, and earnings per share increased from -$1.0292 to $1.443.
D
Sell 11/16/2020Upgraded
BioNTech SE (BNTX) was upgraded to D+ from D on 11/16/2020 due to a large increase in the solvency index, growth index and total return index. Total revenue increased 71.49% from $46M to $78.89M, and the quick ratio increased from 2.81 to 3.79.
D
Sell 4/3/2020Upgraded
BioNTech SE (BNTX) was upgraded to D from D- on 4/3/2020 due to a major increase in the total return index, efficiency index and solvency index. Total capital increased 35.87% from $468.87M to $637.08M, and the quick ratio increased from 3.69 to 3.92.
D
Sell 1/6/2020None
BioNTech SE (BNTX) was downgraded to D- from U on 01/06/2020.
Weiss Ratings